Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 4,198 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Injection Clear all
Completed Phase 2 Interventional Results available

Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency

NCT03716739
View directory record Official record
Conditions
Prostate Cancer
Interventions
Testosterone Cypionate 100 MG/ML, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
40 Years and older · Male only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Phase 1 Interventional

Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

NCT01835730
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
PE0139 Injection, Placebo
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Anniston, Alabama • Hialeah, Florida • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 20, 2026, 9:05 AM EDT
Terminated Phase 2 Interventional Results available

Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.

NCT05142228
View directory record Official record
Conditions
Trigeminal Neuropathy
Interventions
Erenumab-Aooe, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 20, 2026, 9:05 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect

NCT01589081
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Intravenous Nicotine, Progesterone
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

NCT01272219
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
3,731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
73
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 64 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

NCT00423319
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles

NCT03223298
View directory record Official record
Conditions
Pain, Head, Pain Syndrome, Temporomandibular Disorder, Myofascial Pain Syndrome, Myofascial Pain
Interventions
Botulinum toxin type A, 0.9% Sodium Chloride Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

Neurobiology of Bulimia Nervosa

NCT04225221
View directory record Official record
Conditions
Bulimia Nervosa
Interventions
Estradiol, Micronized progesterone, Leuprolide Acetate, Placebo Oral Capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee

NCT05449132
View directory record Official record
Conditions
Osteoarthritis
Interventions
RTX-GRT7039, Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
56
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

NCT00621504
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

NCT03820414
View directory record Official record
Conditions
Herpes Zoster, Varicella Zoster
Interventions
CRV 101, Placebo
Biological
Lead sponsor
Curevo Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

BARDA Securing Anthrax Immunity For the Elderly

NCT03518125
View directory record Official record
Conditions
Anthrax
Interventions
BioThrax, AV7909, Sodium chloride injection USP, 0.9% (placebo)
Biological · Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Lenexa, Kansas • Mt. Pleasant, South Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

NCT05511025
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6234, Placebo, Acetaminophen
Drug · Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 20, 2026, 9:05 AM EDT
Terminated Phase 3 Interventional Results available

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

NCT03151408
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Pracinostat, Placebos, Azacitidine
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
30
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 20, 2026, 9:05 AM EDT
Terminated Phase 1 Interventional

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

NCT01164917
View directory record Official record
Conditions
Cutaneous Lupus, Discoid Lupus, Lupus, Systemic Lupus Erythematosus
Interventions
AMG811, AMG811 Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Stanford, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)

NCT02018250
View directory record Official record
Conditions
Safety and Efficacy
Interventions
MMB4 DMS, Placebo
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence

NCT00758420
View directory record Official record
Conditions
Varicose Veins
Interventions
Varisolve (Polidocanol Endovenous Microfoam), Agitated Saline
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Scottsdale, Arizona • New York, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 20, 2026, 9:05 AM EDT
Terminated Phase 2 Interventional

Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus

NCT05591222
View directory record Official record
Conditions
Discoid Lupus Erythematosus
Interventions
Placebo, Daxdilimab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
North Little Rock, Arkansas • Beverly Hills, California • Fremont, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 20, 2026, 9:05 AM EDT
Terminated Phase 3 Interventional

Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome

NCT02179151
View directory record Official record
Conditions
Prader-Willi Syndrome, Obesity
Interventions
ZGN-440 for Injectable Suspension, ZGN-440 Placebo for Injectable Suspension
Drug
Lead sponsor
Zafgen, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Sacramento, California • San Diego, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

NCT04463251
View directory record Official record
Conditions
Acute ST Segment Elevation Myocardial Infarction
Interventions
RPH-104 80 mg, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Cleveland, Ohio • Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 20, 2026, 9:05 AM EDT
Recruiting Phase 4 Interventional

Magnesium Infusion for Pain Management in Critically Ill Trauma Patients

NCT04166877
View directory record Official record
Conditions
Trauma, Acute Pain
Interventions
Magnesium Sulfate in Parenteral Dosage Form, Normal saline placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Phase 1 Interventional

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

NCT03479892
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC0194-0499, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
22 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Not applicable Interventional

Effect of Reparel Knee Sleeve With Knee Injection

NCT04859764
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Reparel knee sleeve, Corticosteroid injection, Placebo knee sleeve
Device · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 20, 2026, 9:05 AM EDT
Completed Not applicable Interventional Results available

Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome

NCT01511016
View directory record Official record
Conditions
HIV Lipodystrophy
Interventions
Human recombinant leptin ("metreleptin"), Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Oct 20, 2026, 9:05 AM EDT